Literature DB >> 24488417

Patient perceptions of osteoporosis treatment thresholds.

Joan M Neuner1, Marilyn M Schapira.   

Abstract

OBJECTIVE: Many older patients express concerns about medication risks, and have higher risk thresholds than physicians for cardiovascular preventive medications. We hypothesized that patients have relatively high risk thresholds for fracture preventive medications.
METHODS: Women ≥ 60 years old were recruited from 3 primary care internal medicine clinics in Wisconsin. Participants were provided information regarding fracture risks and treatment risks and benefits, followed by a series of vignettes depicting a 70-year-old woman at baseline fracture risks between 5-50%. Fracture risks were shown graphically and treatment side effects were provided for each vignette, and participants were asked to respond regarding whether they would accept treatment. The association of vignette treatment acceptance with participant beliefs regarding medication risks was examined in analyses adjusted for perceived risk of medications, patient numeracy, and prior respondent experience with osteoporosis.
RESULTS: The mean age of women in the cohort was 69.4 years (SD 7.29). Ninety-one percent were non-Hispanic whites, 34% reported a history of fracture, and 20.3% a history of osteoporosis. Subjects varied substantially in their responses to vignettes, but only 51% reported they would accept prescription osteoporosis treatment at the threshold currently recommended by national physician treatment guidelines, and fewer would accept treatment at lower risks. Belief that medications are generally not worth their risks was associated with lower acceptance of treatment at all levels of fracture risk.
CONCLUSION: There is substantial variability in preferences for postmenopausal osteoporosis treatment. Presentation of individualized fracture risks as recommended by current guidelines has potential to allow better targeting to higher-risk patients, but further work is needed regarding how to present this information and counsel patients.

Entities:  

Keywords:  OSTEOPOROSIS; PATIENT SATISFACTION; PRACTICE GUIDELINES; PREVENTIVE MEDICINE; WOMEN

Mesh:

Substances:

Year:  2014        PMID: 24488417      PMCID: PMC4060529          DOI: 10.3899/jrheum.130548

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  40 in total

1.  Bisphosphonates for osteoporosis--where do we go from here?

Authors:  Marcea Whitaker; Jia Guo; Theresa Kehoe; George Benson
Journal:  N Engl J Med       Date:  2012-05-09       Impact factor: 91.245

2.  American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

Authors:  Nelson B Watts; John P Bilezikian; Pauline M Camacho; Susan L Greenspan; Steven T Harris; Stephen F Hodgson; Michael Kleerekoper; Marjorie M Luckey; Michael R McClung; Rachel Pessah Pollack; Steven M Petak
Journal:  Endocr Pract       Date:  2010 Nov-Dec       Impact factor: 3.443

Review 3.  The clinical impact of vertebral fractures: quality of life in women with osteoporosis.

Authors:  D T Gold
Journal:  Bone       Date:  1996-03       Impact factor: 4.398

4.  Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis.

Authors:  B Ettinger; A Pressman; J Schein
Journal:  Am J Manag Care       Date:  1998-10       Impact factor: 2.229

5.  An assessment tool for predicting fracture risk in postmenopausal women.

Authors:  D M Black; M Steinbuch; L Palermo; P Dargent-Molina; R Lindsay; M S Hoseyni; O Johnell
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

6.  Agreement between scales in the measurement of breast cancer risk perceptions.

Authors:  Marilyn M Schapira; Susan L Davids; Timothy L McAuliffe; Ann B Nattinger
Journal:  Risk Anal       Date:  2004-06       Impact factor: 4.000

7.  Use of alendronate and risk of incident atrial fibrillation in women.

Authors:  Susan R Heckbert; Guo Li; Steven R Cummings; Nicholas L Smith; Bruce M Psaty
Journal:  Arch Intern Med       Date:  2008-04-28

8.  Using a drug facts box to communicate drug benefits and harms: two randomized trials.

Authors:  Lisa M Schwartz; Steven Woloshin; H Gilbert Welch
Journal:  Ann Intern Med       Date:  2009-02-16       Impact factor: 25.391

9.  Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

10.  A simple risk score for the assessment of absolute fracture risk in general practice based on two longitudinal studies.

Authors:  Saskia M F Pluijm; Bart Koes; Chris de Laet; Natasja M Van Schoor; Natalia O Kuchuk; Fernando Rivadeneira; Johan P Mackenbach; Paul Lips; Huibert A Pols; Ewout W Steyerberg
Journal:  J Bone Miner Res       Date:  2009-05       Impact factor: 6.741

View more
  5 in total

Review 1.  Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences.

Authors:  Axel Finckh; Monica Escher; Matthew H Liang; Nick Bansback
Journal:  Curr Rheumatol Rep       Date:  2016-08       Impact factor: 4.592

2.  A pilot randomized controlled trial of a decision aid with tailored fracture risk tool delivered via a patient portal.

Authors:  A J Smallwood; M M Schapira; M Fedders; J M Neuner
Journal:  Osteoporos Int       Date:  2016-09-19       Impact factor: 4.507

3.  Disparities in osteoporosis treatments.

Authors:  Z Liu; J Weaver; A de Papp; Z Li; J Martin; K Allen; S Hui; E A Imel
Journal:  Osteoporos Int       Date:  2015-07-28       Impact factor: 4.507

4.  Screening to prevent fragility fractures among adults 40 years and older in primary care: protocol for a systematic review.

Authors:  Michelle Gates; Jennifer Pillay; Guylène Thériault; Heather Limburg; Roland Grad; Scott Klarenbach; Christina Korownyk; Donna Reynolds; John J Riva; Brett D Thombs; Gregory A Kline; William D Leslie; Susan Courage; Ben Vandermeer; Robin Featherstone; Lisa Hartling
Journal:  Syst Rev       Date:  2019-08-23

5.  Preventive drugs for Huntington's disease: A choice-based conjoint survey of patient preferences.

Authors:  Marcus C Parrish; Andrea Hanson-Kahn; V Srinivasan; Kevin V Grimes
Journal:  J Clin Transl Sci       Date:  2022-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.